Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line

Journal of Gene Medicine

Volumn 6, Issue 4, 2004, Pages 374-386

  Lemoine, François M ^a   Mesel Lemoine, Mariana ^a   Cherai, Mustapha ^a   Gallot, Géraldine ^b   Vié, Henri ^b   Leclercq, Virginie ^a   Trébèden Negre, Hélène ^a   Mammès, Olivier ^a   Boyer, Olivier ^a   Noguiez Hellin, Patricia ^a,c   Klatzmann, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c GÉNÉTHON   (France)

Author keywords

Bicistronic retroviral vectors; Graft versus host disease; HSV1 TK gene; Human T cells; Packaging cells; Thy1 gene

Indexed keywords

GANCICLOVIR; INTERLEUKIN 2; OKT 3; RETROVIRUS VECTOR; THY 1 ANTIGEN; THYMIDINE KINASE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SELECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE CONTROL; GENE REPLICATION; GENETIC TRANSDUCTION; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK REDUCTION; SUICIDE GENE THERAPY; SUPERNATANT; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTIGENS, THY-1; BASE SEQUENCE; CELL LINE; CELLS, CULTURED; GANCICLOVIR; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; RETROVIRIDAE; T-LYMPHOCYTES; THYMIDINE KINASE; TRANSDUCTION, GENETIC; VIRUS CULTIVATION;

GIBBON APE LEUKEMIA VIRUS;

EID: 13644270754     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.538     Document Type: Article

References (59)

1. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15 433-444.
2. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
3. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
5. Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999; 11: 509-515.
6. Atkinson K, Storb R, Prentice RL, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979; 53: 720-731.
7. Witherspoon RP, Kopecky K, Storb RF, et al. Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation 1982; 33: 143-149.
8. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997; 157: 79-109.
9. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832-843.
10. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
11. Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664-672.
12. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997; 157: 61-72.
13. Cohen JL, Boyer O, Salomon B, et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636-4645.
14. Helene M, Lake-Bullock V, Bryson JS, et al. Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene. J Immunol 1997; 158: 5079-5082.
15. Cohen JL, Boyer O, Klatzmann D. Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? Immunol Today 1999; 20: 172-176.
16. Cohen JL, Saron MF, Boyer O, et al. Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease. Hum Gene Ther 2000; 11: 2473-2481.
17. Litvinova E, Maury S, Boyer O, et al. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood 2002; 100: 2020-2025.
18. Gallardo H, Tan C, Sadelain M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther 1997; 4 1115-1119.
19. Tiberghien P, Reynolds CW, Keller J, et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994; 84: 1333-1341.
20. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
21. Link CJ Jr, Burt RK, Traynor AE, et al. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. Hum Gene Ther 1998; 9: 115-134.
22. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63-72.
23. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 1998; 9: 2243-2251.
24. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296 497.
25. Conneally E, Bardy P, Eaves CJ, et al. Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer. Blood 1996; 87: 456-464.
26. Hough MR, Takei F, Humphries RK, et al. Defective development of thymocytes overexpressing the costimulatory molecule, heat-stable antigen. J Exp Med 1994; 179: 177-184.
27. Seki T, Spurr N, Obata F, et al. The human thy-1 gene: structure and chromosomal location. Proc Natl Acad Sci U S A 1958; 82: 6657-6661.
28. Rigg RJ, Chen J, Dando JS, et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 1996; 218: 290-295.
29. Movassagh M, Desmyter C, Baillou C, et al. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 1998; 9: 225-234.
30. Movassagh M, Boyer O, Burland MC, et al. Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum Gene Ther 2000; 11: 1189-1200.
31. Cosset F-L, Takeuchi Y, Battini J-L, et al. High titer packaging cells producing recombinant retrovirus resistant to human serum. J Virol 1995; 69: 7430-7436.
32. Colicelli J, Goff SP. Sequence and spacing requirements of a retrovirus integration site. Mol Cell Biol 1988; 199: 47-59.
33. Shinnick TM, Lerner RA, Sutcliffe GJ. Nucleotide sequence of moloney leukaemia virus. Nature 1981; 293: 543-548.
34. Rees S, Coote J, Stables J, et al. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996; 20: 102-110.
35. Miller AD, Garcia JV, von Suhr N, et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
36. Delassus S, Sonigo P, Wain-Hobson S. Genetic organization of gibbon ape leukemia virus. Virology 1989; 173: 205-213.
37. Danos O, Mulligan RC. Safe and efficient generation of recombinant retrovirus with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 1988; 85: 6460-6464.
38. Ott D, Friedrich R, Rein A. Sequence analysis of amphotropic and 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses. J Virol 1990; 64: 757-766.
39. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024-7028.
40. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, 1989.
41. Morozov V, Noguiez-Hellin P, Laune S, et al. Plasmovirus: replication cycle of a novel nonviral/viral vector for gene therapy. Cancer Gene Ther 1997; 4: 286-293.
42. Rey MA, Spire B, Dormont D, et al. Characterisation of the RNA dependent DNA polymerase of a new human T lymphotropic retrovirus. Biochem Biophys Res Commun 1984; 121: 126-133.
43. Noguiez-Hellin P, Robert-Le Meur M, Salzmann J-L, et al. Plasmoviruses: nonviral/viral vectors for gene therapy. Proc Natl Acad Sci U S A 1996; 93: 4175-4180.
44. Gallardo HF, Tan C, Ory D, et al. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 1997; 90: 52-57.
45. Gaschet J, Mahe B, Milpied N, et al. Specificity of T cells invading the skin during acute graft-versus-host disease after semiallogeneic bone marrow transplantation. J Clin Invest 1993; 91: 12-20.
46. Gaschet J, Trevino MA, Cherel M, et al. HLA-target antigens and T-cell receptor diversity of activated T-cells invading the skin during acute graft-versus-host. Blood 1996; 87: 2345-2353.
47. Gallot G, Vivien R, Ibish C, et al. Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD24 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination. J Immunol 2001; 167: 4196-4206.
48. Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev 1991; 119: 65-93.
49. Cochet M, Pannetier C, Regnault A, et al. Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol 1992; 22: 2639-2647.
50. Pannetier C, Cochet M, Darche S, et al. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A 1993; 90: 4319-4323.
51. Takeuchi Y, Cosset F-L, Lachmann PJ, et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001-8007.
52. Garin MI, Garret E, Tiberghien P, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpex simplex virus thymidine kinase gene. Blood 2001; 97: 122-129.
53. Davis JL, Witt RM, Gross PR, et al. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum Gene Ther 1997; 8: 1459-1467.
54. Habib NA, Hodgson HJ, Lemoine N, et al. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 1999; 10: 2019-2034.
55. Bunnell BA, Muul LM, Donahue RE, et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1995; 92 7739-7743.
56. Nemoto E, Stohlman S, Dennert G. Release of a glycosylphosphatidylinositol-anchored ADP-ribosyltransferase from cytotoxic T cells upon activation. J Immunol 1996; 156: 85-92.
57. Kustikova OS, Wahlers A, Kuhlcke K, et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; in press.
58. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
59. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003; 348: 193-194.